Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AXGN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
AXGN reported $111.4M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AXGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Mathew P. Arens | 5%+ holder (13G) | 4,072,910 | 7.58% | 2026-06-30 |
| Divisadero Street Capital Management, LP | Institution (13G, 5%+) | 3,983,783 | 7.41% | 2026-10-02 |
Share count 53,761,513 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-08-25 | — | BLA | +23.1% | -9% | -0.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AXGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →